On July 13, 2020 Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, reported that it is hosting a July 23 webinar titled, "Emerging Treatment Approaches for Higher Risk Myelodysplastic Syndromes (Press release, Notable Labs, JUL 13, 2020, View Source [SID1234561825])." Speakers from the Stanford Cancer Institute and the MDS Foundation will explore current standards of care for MDS as well as emerging treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be moderated by Dr. Sandra Kurtin, a member of the MDS Foundation Board of Directors, as well as the Chair of MDS Foundation’s International Nurse Leadership Board. The main speaker will be Dr. Michael Spinner, Instructor in the Division of Oncology at the Stanford Cancer Institute.

Drs. Kurtin and Spinner will discuss:

The current standard treatment approach for higher risk MDS
Treatment options for patients who relapse or do not respond to standard therapies
Novel targeted therapies, immunotherapies, and new technologies being investigated
This free event takes place on July 23 at 10am PT. To register, visit View Source